ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Systemic sclerosis"

  • Abstract Number: 0963 • ACR Convergence 2023

    Anti-Topoisomerase Antibody in dcSSc: Unravelling Its Intracellular Effects in Systemic Sclerosis

    Maithri Aspari1, Josephine Geertsen Keller-Socin1, Stinne Greisen2, Esben Naeser3, Klaus Soendergaard4, Birgitta R Knudsen5, Voon Ong6, Christopher Denton7, David Abraham7 and Bent Deleuran1, 1Aarhus University, Aarhus, Denmark, 2Aarhus University/Aarhus University Hospital, Aarhus, Denmark, 3Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 4Aarhus University Hospital, Aarhus, Denmark, 5Institute for molecular Biology, Aarhus University, Aarhus, Denmark, 6UCL Medical School Royal Free Campus, London, United Kingdom, 7University College London, London, United Kingdom

    Background/Purpose: The presence of autoantibodies, especially directed towards topoisomerase I (ATA), in diffuse cutaneous Systemic Sclerosis (dcSSc) is known to be associated with severe clinical…
  • Abstract Number: 1529 • ACR Convergence 2023

    Mycophenolate Mofetil Use in Clinical Practice: Persistence on Therapy and Long-term Adverse Events in a Multicentric Cohort of Scleroderma Patients

    Silvia Bosello1, enrico De Lorenzis1, lucrezia verardi1, gerlando Natalello1, pier giacomo Cerasuolo1, Stefano Di Donato2, Greta Pellegrino3, Giacomo De Luca4, Corrado Campochiaro5, Gemma Lepri6, Laura Cometi7, Fabio Cacciapaglia8, Giuseppe Armetano9, Marco De Pinto10, Francesca Motta11, Maria De Santis11, Dilia Giuggioli12, Nicoletta Del Papa9, Florenzo Iannone13, Serena Guiducci7, valeria Riccieri14, Maria Antonietta D'Agostino1 and Francesco Del Galdo2, 1Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy, 2University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom, 3Department of Rheumatology, La Sapienza University of Rome, Rome, Italy, 4Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milano, Italy, 5IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy, 6Department of Experimental and Clinical medicine, Division of Rheumatology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy, 7University of Florence, Unit of Rheumatology Azienda Ospedaliera Careggi, Florence, Italy, 8Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari, Bari, Italy, 9Scleroderma Clinic, Dipartimento di Reumatologia, ASST Gaetano Pini CTO, Milano, Italy, 10Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto, Università di Modena e Reggio Emilia, Modena, Modena, Italy, 11Reumatologia e Immunologia Clinica, IRCCS Humanitas Research Hospital, Humanitas University, Rozzano, Milan, Italy, 12Scleroderma Unit, Rheumatology Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy, 13Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, 14Department of Clinical, Internal and Cardiovascular Specialities, Sapienza University of Rome, Roma, Italy

    Background/Purpose: Mycophenolate mofetil (MMF) is a first-line immunosuppressant treatment for systemic sclerosis (SSc), particularly for patients with interstitial lung disease (ILD) and diffuse skin involvement.…
  • Abstract Number: 1930 • ACR Convergence 2023

    Blue Digit Syndrome as the Initial Presentation of Various Diseases: A Case Series

    Raquel Ugena García1, Juan José Lluch Galcerá2, Cristina Calomarde Gomez1, Ivette Casafont-Sole3 and Lourdes Mateo Soria2, 1Rheumatology department. Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 2Hospital Germans Trias i Pujol, Badalona, Spain, 3Hospital Universitari Germans Trias i Pujol, Badalona, Spain

    Background/Purpose: Blue Digit Syndrome (BDS) represents the cutaneous manifestation of numerous diseases that cause blue discoloration in one or more fingers in the absence of…
  • Abstract Number: 2593 • ACR Convergence 2023

    FT011 for the Treatment of Systemic Sclerosis. Results from a Phase II Study

    Christopher Denton1, Wendy Stevens2, Nicole Kruger3, Michelle Papadimitriou4, Fay Khong4, Michelle Bradney3, Darren Kelly4 and Robert Lafyatis5, 1University College London, London, United Kingdom, 2Department of Rheumatology, St Vincent's Hospital Melbourne, Fitzroy, Australia, 3Certa Therapeutics, Melbourne, Australia, 4Certa Therapeutics and Melbourne University, Melbourne, Australia, 5University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune disease characterized by vascular damage, inflammation, and fibrosis of the skin and organs, with no approved disease modifying…
  • Abstract Number: 0129 • ACR Convergence 2023

    Rising Incidence and High Mortality of Systemic Sclerosis: A Population-based Cohort Study (2010-2020)

    Anukul Karn1, Sara Achenbach2, Alicia Hinze3, Cynthia Crowson1 and Ashima Makol2, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, MN, Rochester, MN, 3Mayo Clinic - Rochester, MN, Rochester, MN

    Background/Purpose: Systemic Sclerosis (SSc) is a rare chronic inflammatory disease characterized by immune-mediated dysfunction, vasculopathy and widespread internal organ fibrosis; and the highest case fatality…
  • Abstract Number: 0623 • ACR Convergence 2023

    Nailfold Capillaroscopy in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Treated with Nintedanib

    Vanessa Smith1, Christopher Denton2, Ariane Herrick3, Carina Ittrich4, Margarida Alves5 and Maurizio Cutolo6, 1Ghent University Hospital, Gent, Belgium, 2University College London, London, United Kingdom, 3University of Manchester, Salford, United Kingdom, 4Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany, Biberach an der Riss, Germany, 5Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, 6Laboratory of Experimental Rheumatology, Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic, Genova, Italy

    Background/Purpose: Microvascular damage is part of the pathogenesis of systemic sclerosis and is associated with internal organ involvement. Nintedanib is a tyrosine kinase inhibitor approved…
  • Abstract Number: 0644 • ACR Convergence 2023

    Prediction of Stable SSc-ILD Depends on Definition of ILD Progression

    Anna-Maria Hoffmann-Vold1, Liubov Petelytska2, Havard Fretheim1, Trond Mogens Aaløkken3, Mike Becker4, Cathrine Brunborg5, Cosimo Bruni6, Christian Clarenbach7, Phuong Phuong Diep8, Rucsandra Dobrota6, Michael Durheim9, Muriel Elhai10, Thomas Frauenfelder11, Suzana Jordan6, Emily Langballe12, Carina Mihai6, Oyvind Midtvedt1, Oyvind Molberg13 and Oliver Distler6, 1Oslo University Hospital, Oslo, Norway, 2Bogomolets National Medical University, Kyiv, Ukraine, 3Dept of Radiology, Oslo University Hospital, Oslo, Norway, 4Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 5Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital - Rikshospitalet, Oslo, Norway, 6Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 7Dept of Pulmonology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 8Dept of Respiratory diseases, University Hospital Oslo, Oslo, Norway, 9Dept of Respiratory diseases, Oslo University Hospital, Oslo, Norway, 10University Hospital zurich, University of Zurich, Zurich, Switzerland, 11Dept of Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 12Universitetet i Oslo, Oslo, Norway, 13Dept of Rheumatology, University Hospital Oslo, Oslo, Norway

    Background/Purpose: Progression of interstitial lung disease (ILD) reduces long-term survival in patients with systemic sclerosis (SSc), and aggressive treatment and tight monitoring should be considered.…
  • Abstract Number: 0666 • ACR Convergence 2023

    Troponin I Levels in Systemic Sclerosis Patients with Myocardial Involvement

    Eva Hoekstra1, Sophie Liem1, Nivine Levarht1, Cynthia Fehres1, Saad Ahmed1, Nina Ajmone Marsan2, Thomas Huizinga1 and Jeska de Vries-Bouwstra1, 1Leiden University Medical Center, Leiden, Netherlands, 2Department of Cardiology, Heart Lung Centre, Leiden University Medical Centre, Leiden, Netherlands

    Background/Purpose: As primary myocardial involvement in systemic sclerosis (SSc) is associated with worse prognosis, research on diagnostic tools for recognition is essential. Troponin I was…
  • Abstract Number: 0940 • ACR Convergence 2023

    A Novel Therapeutic Opportunity in Systemic Sclerosis: The Fibrolytic Activities of a Specialized Macrophage Secretome

    Françis Bonnefoy1, Susanne Behlke2 and Sylvain Perruche1, 1Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Institute/MedINNPharma, Besançon, France, 2MedINNPharma, Besançon, France

    Background/Purpose: Systemic sclerosis (SSc) a complex and rare immune-mediated connective tissue disorder characterized by microvascular damage, inflammatory cell infiltration, and excessive deposition of extracellular matrix…
  • Abstract Number: 1035 • ACR Convergence 2023

    Diagnostic and Educational Utility of an Ultrasound Protocol for Evaluation of Hand Pain in Systemic Sclerosis

    Meridith Balbach, Tracy Frech, Nicholson Chadwick, Kevin Byram and Erin Chew, Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Hand impairment is a prevalent issue among systemic sclerosis (SSc) patients and contributes to disability and diminished quality of life. Managing hand pain can…
  • Abstract Number: 1533 • ACR Convergence 2023

    Long-term Use of Rituximab in Systemic Sclerosis: A Real-life Italian Multicentre Study

    Giacomo De Luca1, Corrado Campochiaro2, Fabio Cacciapaglia3, Nicoletta Del Papa4, Elisabetta Zanatta5, Paolo Airò6, Maria Grazia Lazzaroni6, Dilia Giuggioli7, Maria De Santis8, Gabriella Alonzi9, Stefano Stano10, Marco Binda5, Beatrice Moccaldi5, Antonio Tonutti11, Florenzo Iannone12, Maria Antonietta D'Agostino9, Lorenzo Dagna13, marco Matucci Cerinic14 and Silvia Bosello15, 1Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milano, Italy, 2IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy, 3Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari, Bari, Italy, 4Scleroderma Clinic, Dipartimento di Reumatologia, ASST Gaetano Pini CTO, Milano, Italy, 5Rheumatology Unit, Padova University Hospital, Padova, Italy, 6Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy, 7Scleroderma Unit, Rheumatology Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy, 8Reumatologia e Immunologia Clinica, IRCCS Humanitas Research Hospital, Humanitas University, Rozzano, Milan, Italy, 9Scleroderma Unit, Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, 10Rheumatology Unit - DiMePRe-J University of Bari, Bari, Italy, 11Humanitas University and Humanitas Research Hospital, Rozzano, Italy, 12Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, 13Department of Internal Medicine, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy, 14Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, 15Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy

    Background/Purpose: Rituximab(RTX) has been used for the management of systemic sclerosis(SSc). Its efficacy has been recently confirmed in a phase III clinical trial with extension…
  • Abstract Number: 2094 • ACR Convergence 2023

    Increasing Collaboration, Education, and Awareness of Scleroderma Through an Interprofessional Education Program: Emphasizing the Importance of a Multidisciplinary Team and the Patient as the Primary Educator

    Corey Fellon1, Hannah Bowen2 and Lee Shapiro3, 1Albany Medical College, Albany, NY, 2Steffens Scleroderma Foundation, Batavia, NY, 3Albany Medical College, Stillwater, NY

    Background/Purpose: Scleroderma is a condition that can affect almost every organ system and thus requires an interprofessional team to optimally manage symptoms and improve patient…
  • Abstract Number: 2594 • ACR Convergence 2023

    Trajectories of Forced Vital Capacity (FVC) in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

    Oliver Distler1, Madelon Vonk2, Arata Azuma3, Maureen Mayes4, Dinesh Khanna5, Kristin B Highland6, Gerrit Toenges7, Margarida Alves8 and Yannick Allanore9, 1Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 2Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 3Pulmonary Medicine and Oncology, Nippon Medical School, Tokyo, Japan, and Meisei Hospital, Saitama, Japan, 4Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, 5University of Michigan, Ann Arbor, MI, 6Cleveland Clinic, Cleveland, OH, 7Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany, 8Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, 9Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France

    Background/Purpose: The SENSCIS trial enrolled patients with SSc-ILD without a requirement for them to have evidence of recent progression. During the trial, nintedanib reduced the…
  • Abstract Number: 0266 • ACR Convergence 2023

    E-selectin, ICAM-1 and ET-1 Biomarkers Address the Concern of the Challenging Diagnosis of Interstitial Lung Disease in Patients with Autoimmune Diseases

    Verónica Pulito-Cueto1, Sara Remuzgo-Martinez2, Fernanda Genre Romero2, Belén Atienza-Mateo3, Victor Mora-Cuesta4, David Iturbe-Fernández4, Leticia Lera-Gómez5, María Sebastián-Mora1, Virginia Portilla1, Alfonso Corrales1, Ricardo Blanco1, Jose Cifrian6, Miguel A Gonzalez-Gay7 and Raquel López-Mejías1, 1Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, 2IDIVAL, Santander, Spain, 3Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 4Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital, Santander, Spain, 5Hospital Universitario Marqués de Valdecilla, Santander, Spain, 6Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital; School of Medicine, Cantabria University, Santander, Spain, 7IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain

    Background/Purpose: Interstitial lung disease (ILD) constitutes one of the most critical comorbidities in autoimmune diseases (AD), particularly in rheumatoid arthritis (RA) and systemic sclerosis (SSc)…
  • Abstract Number: 0624 • ACR Convergence 2023

    Outcomes in Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Based on Serological Profiles: Focus on Anti-Centromere Antibody (ACA) and Anti-RNA Polymerase III (ARA) Antibodies

    Elizabeth Volkmann1, Shervin Assassi2, Christopher Denton3, Rozeta Simonovska4, Steven Sambevski5 and Elana Bernstein6, 1University of California Los Angeles, Los Angeles, CA, 2University of Texas McGovern Medical School at Houston, Houston, TX, 3University College London, London, United Kingdom, 4Mainanalytics GmbH, Sulzbach (Taunus), Sulzbach, Germany, 5Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, 6Division of Rheumatology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY

    Background/Purpose: Autoantibody profiles are associated with organ involvement and outcomes in patients with SSc. Anti-topoisomerase I antibody (ATA) positivity has been associated with a greater…
  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • 16
  • …
  • 46
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology